{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["133"],"submitter":["Zens KD"],"pubmed_abstract":["<h4>Objectives</h4>The correlate(s) of protection against SARS-CoV-2 remain incompletely defined. Additional information regarding the combinations of antibody and T cell-mediated immunity which can protect against (re)infection is needed.<h4>Methods</h4>We conducted a population-based, longitudinal cohort study including 1044 individuals of varying SARS-CoV-2 vaccination and infection statuses. We assessed spike (S)- and nucleocapsid (N)-immunoglobulin(Ig)G and wildtype, Delta, and Omicron-neutralizing antibody (N-Ab) activity. In a subset of 328 individuals, we evaluated S, membrane (M), and N-specific T cells. Three months later, we reassessed Ab (n = 964) and T cell (n = 141) responses and evaluated factors associated with protection from (re)infection.<h4>Results</h4>At the study star"],"journal":["International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"],"pagination":["18-26"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10159929"],"repository":["biostudies-literature"],"pubmed_title":["Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022 - evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses."],"pmcid":["PMC10159929"],"pubmed_authors":["Menges D","Zens KD","Frei A","Llanas-Cornejo D","Fehr JS","Puhan MA","Munz C"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022 - evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses.","description":"<h4>Objectives</h4>The correlate(s) of protection against SARS-CoV-2 remain incompletely defined. Additional information regarding the combinations of antibody and T cell-mediated immunity which can protect against (re)infection is needed.<h4>Methods</h4>We conducted a population-based, longitudinal cohort study including 1044 individuals of varying SARS-CoV-2 vaccination and infection statuses. We assessed spike (S)- and nucleocapsid (N)-immunoglobulin(Ig)G and wildtype, Delta, and Omicron-neutralizing antibody (N-Ab) activity. In a subset of 328 individuals, we evaluated S, membrane (M), and N-specific T cells. Three months later, we reassessed Ab (n = 964) and T cell (n = 141) responses and evaluated factors associated with protection from (re)infection.<h4>Results</h4>At the study star","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2025-05-18T13:37:38.398Z","creation":"2024-11-21T08:24:16.22Z"},"accession":"S-EPMC10159929","cross_references":{"pubmed":["37149211"],"doi":["10.1016/j.ijid.2023.04.407"]}}